Research Reference / 5Ξ±-Reductase
Topical finasteride is studied as a way to investigate local 5Ξ±-reductase inhibition, androgen metabolism and DHT-associated follicle pathways. Understanding the distinction between 0.1% and 0.1 mg/mL is essential: these are not the same concentration.
What does finasteride do in research?
Finasteride inhibits 5Ξ±-reductase, an enzyme that converts testosterone into the more potent androgen dihydrotestosterone (DHT). Because androgen signaling is involved in follicle miniaturization in androgenetic alopecia, researchers have investigated both oral and scalp-directed finasteride formulations.
The clinical evidence for finasteride belongs to defined prescription drug formulations, specified concentrations and methods of delivery. It cannot be assumed to apply unchanged to an unrelated liquid, solvent system or laboratory research product.
Topical finasteride 0.1% vs 0.1 mg/mL: the conversion
For weight-per-volume (w/v) solutions, a concentration of 0.1% means 0.1 grams of finasteride per 100 mL of total solution. That equals 1 mg/mL. By contrast, 0.1 mg/mL equals 0.01% w/vβa tenfold difference in strength.
| Label expression | Equivalent | Mass in 30 mL, if volume is 30 mL |
|---|---|---|
| 0.1% w/v | 1 mg/mL | 30 mg |
| 0.1 mg/mL | 0.01% w/v | 3 mg |
These conversions describe concentration units, not a recommended amount to apply. Always confirm the actual labeled formulation and batch documentation; a product image filename or a web description alone is not analytical verification.
What has human topical-finasteride research shown?
A 24-week randomized, double-blind Phase III study published in the Journal of the European Academy of Dermatology and Venereology compared a specific topical finasteride spray formulation with placebo, while also measuring systemic exposure against oral finasteride. The trial enrolled 458 men, with 446 evaluated for safety.
The authors reported a larger adjusted increase in target-area hair count at week 24 for topical finasteride than placebo (20.2 versus 6.7 hairs). The formulation studied was a 0.25% spray solution, not a generic 0.1% or 0.1 mg/mL laboratory product. These results should not be presented as proof of efficacy for a different formulation.
Although the study reported lower average systemic exposure for that topical formulation than for oral finasteride, lower is not zero. Absorption and adverse effects remain important considerations in assessing any topical preparation.
FDA safety warning on compounded topical finasteride
The U.S. FDA issued an April 2025 alert about adverse-event reports associated with compounded topical finasteride products. Compounded topical preparations are not FDA-approved products, and the agency warned that users may be unaware of potential systemic risks. These reports do not describe the safety of any particular research lot, but they are material context for interpreting the category.
Finasteride can be absorbed through skin. Research handling should follow the relevant safety documentation, particularly around exposure risks. This page does not provide application or medical-use instructions.
Topical finasteride research FAQs
Is 0.1% finasteride the same strength as 0.1 mg/mL?
No. 0.1% w/v equals 1 mg/mL, while 0.1 mg/mL equals 0.01% w/v. They differ by a factor of ten.
Is topical finasteride FDA approved in the United States?
There is no FDA-approved topical finasteride drug product in the United States as of this page’s review date. An FDA-approved oral medicine is not the same as approval of a topical preparation.
Can clinical trial results be used to promote a research liquid?
Not as proof of performance for a different formulation. Clinical outcomes depend on the tested product, dosing protocol, delivery system and study population.
How do I verify an advertised finasteride concentration?
Use the precise lot number, product label and a matching analytical report where measured concentration or content is actually reported. Visit the Disguised Alpha COA portal for any available lot documents.
Scientific and regulatory references
- Piraccini BM et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol. 2022. DOI: 10.1111/jdv.17738.
- U.S. FDA Compounding Risk Alerts β April 22, 2025 alert concerning compounded topical finasteride.
- FDA MedWatch notice, April 25, 2025 β reported risks and consumer communication.
Research and editorial disclosure: Disguised Alpha publishes this educational reference and sells some of the research materials mentioned. Findings from independent investigators or drug developers do not establish the identity, performance, safety or therapeutic efficacy of Disguised Alpha formulations. Research-use-only materials are not intended for human or animal administration, diagnosis, prevention or treatment. This page does not provide dosing advice. Source review: October 29, 2026.